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SALVAGE AND DISEASE CONTROL OF AGGRESSIVE HISTOLOGY NON-
HODGKIN’S LYMPHOMA BY ALLOGENEIC STEM CELL TRANSPLANTA-
TION
Kuruvilla, J.1, Bao, Q.1, Suski, A.1, Gupta, V.1, Lipton, J.H.1,
Minden, M.D.1, Messner, H.A.1 1Princess Margaret Hospital, Toronto,
ON, Canada.
Introduction: Allogeneic SCT (Allo-SCT) remains an option
for patients (pts) who have failed or are ineligible for autologous
SCT (ASCT) or if their long term disease control after ASCT is
likely to be suboptimal. Our program employs a strategy using
allo-SCT for patients with high risk disease based on clinical
characteristics and prior therapy.
Methods: 36 pts with AG-NHL (diffuse large b cell lymphoma
[DLBCL] and variants, follicular large cell or follicular grade 3
[FL3], biopsy proven aggressive histology transformation of indo-
lent lymphoma [TRL] or peripheral T cell lymphoma [PTCL])
underwent allo-SCT at our institution between Sept 1989 and Dec
2005. Patients were in a chemosensitive remission at the time of
SCT. The conditioning regimen consisted of busulfan (1 mg/kg
PO q6h X4 days between 1989-200 and 3.2 mg/kg IV daily X 4days
subsequently) and cyclophosphamide 60 mg/kg X 2 days. Cyclo-
phosphamide 60 mg/kg X 2 days and TBI 12 Gy was used for
unrelated donor SCT. GVHD prophylaxis was with cyclosporine
A and methotrexate.
Results: There were 20 males and 16 females. The median age
at the time of transplant was 47 years (range 20 - 62). Histologic
subtype was: DLBCL and variants: 13, FL3: 5, TRL: 17, PTCL: 1.
The median number of prior chemotherapy regimens was 3 (range
1 - 7) and was unavailable in 5. Prior anthracycline: 36, prior
platinum-based: 29, prior mini-BEAM: 14, prior auto-SCT: 5,
prior rituximab: 3.The median time from diagnosis to allo-SCT
was 29 months (range 7 – 218). One patient underwent RIC SCT.
Graft source was: matched related (MRD) bone marrow (BM): 26,
MRD peripheral blood stem cells (PBSC): 4, Mismatch related
(MMRD) bone marrow (BM): 2, matched unrelated donor (MUD)
BM: 2, and syngeneic BM: 2. The ﬁve year overall survival of the
entire cohort was 50% (95% CI: 33% - 67%). Treatment-related
mortality was 12/36 (33%) and the relapse rate was 4/36 (11%).
Non-relapse mortality was 1 pt (3%). 2 out of the 4 relapses
occurred over 5 years after SCT (1600 and 1828 days post-SCT).
Conclusions: This cohort includes a high proportion of trans-
formed lymphoma and heavy pre-treatment with a median of 3
prior chemotherapy regimens. TRM remains a problem and re-
duced intensity transplants may improve on these results. How-
ever, long-term follow-up of these strategies will be needed to
determine their role in the management of aggressive NHL.
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NONMYELOABLATIVE STEM CELL TRANSPLANTATION IN PATIENTS
WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: POOR EVI-
DENCE OF AN EFFICACIOUS GRAFT-VERSUS-HODGKIN’S LYMPHOMA
EFFECT
Lerner, D.1, Azevedo, A.M.1, Tavares, R.d.C.B.1, Nogueira, M.C.1,
Maiolino, A.2, Bouzas, L.F.1 1Centro de Transplante de Medula O´ssea,
Instituto Nacional de Caˆncer, Rio de Janeiro, RJ, Brazil; 2Universidade
Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.
We report the results of reduced-intensity conditioning (RIC)
allogeneic stem cell transplantation (allo-SCT) and short immu-
nosuppression in 16 patients with advanced Hodgkin lymphoma
(HL), 15 of whom (93%) had progression of disease after previous
autologous transplantation. Nine patients were males (56%), me-
dian age was 27 years (19-43), number of previous treatment
courses was 4 (3-6). Donors were HLA-matched siblings (14),
matched unrelated volunteers (1) and 4:6 matched cord blood (CB)
(1). Source of stem cells was: mobilized peripheral blood (PB) (15)
and CB (1). All the patients received an RIC protocol (ﬂudarabine
125 mg/m2 i.v. plus cyclophosphamide 120 mg/kg i.v.). Unrelated
recipients also received rabbit ATG 7.5 mg/kg and 200 cGy TBI.
GVHD prophylaxis was done with cyclosporine and “mini-meth-
otrexate” (1055 mg/m2). Disease status at allo-SCT was refrac-
tory relapse (12), sensitive relapse (3) or untreated relapse (1). Four
patients (25%) died from early (D100) transplant-related mor-
tality after allo-SCT, two of them before engraftment. The median
time to neutrophil recovery ( 500/ml) was 14 days, and to platelet
recovery ( 20,000/ml) was 19 days. All patients who engrafted
reached full chimerism without the need for additional donor
lymphocyte infusion (DLI). Acute GVHD  grade II was diag-
nosed in 6/13 patients (46%) and chronic GVHD in 7/12 patients
(58%), 5 with extensive cGVHD. Two patients received DLI for
treatment of relapse. Five patients (31%) are alive with a median
follow-up of 28 months (8-50). Only 1 patient is alive in complete
remission with a follow-up of 8 months. Our results sugest that
allo-RIC in heavily pretreated HL patients has an acceptable early
transplant-related mortality and that extensive cGVHD does not
appear to protect from relapse, providing a poor evidence for the
existence of a potent graft-versus-Hodgkin lymphoma effect.
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A RANDOMIZED PHASE I TRIAL OF MELPHALAN  BORTEZOMIB AS
CONDITIONING FOR AUTOLOGOUS TRANSPLANT FOR MYELOMA: THE
EFFECT OF SEQUENCE OF ADMINISTRATION
Lonial, S.1, Kaufman, J.1, Langston, A.A.1, Khoury, H.J.1, Torre, C.1,
Lechowicz, M.J.1, Flowers, C.1, Waller, E.K.1 1Winship Cancer Insti-
tute, Emory University, Atlanta, GA.
Background: High dose therapy and autologous transplant
(HDT) clearly beneﬁts most patients with myeloma, but the addi-
tion of other chemotherapeutics or TBI to high dose melphalan
(M) does not improve outcomes. Bortezomib (B) is a proteasome
inhibitor which synergizes with chemotherapy due to its effects on
DNA repair enzymes. Recent data has shown that B upregulates
the anti-apoptotic protein MCL-1, which would suggest that the
sequence of administration may be critical to the combination of B
and M. We hypothesize that B followed by M is inferior to M
followed by B. To test this hypothesis, we designed a randomized
phase I trial combining B and Melphalan 200 mg/m2 (Mel200) in
order to determine the toxicity, optimal dose and sequence of
administration.
Methods: Patients were randomized to receive either B 24 hours
before Mel 200 or B 24 hours after Mel 200. Doses for B range
from 1.0mg/m2 up to 1.6mg/m2 as deﬁned using a Basyian phase
I design. Standard transplant criteria were used for enrolling pa-
tients with the addition of requiring measurable numbers of plasma
cells within the marrow at the time of transplant (5% plasma cells
by biopsy or M-protein 1.0). Enrolled patients underwent BM
aspirate on day -4 (before B) and day 0 (before PBSC infusion).
Bone marrows were tested for annexin V staining, and myeloma
cells were sorted for protein analysis. Routine demographics, tox-
icity, and engraftment data was also collected.
Results: Eleven patients have been enrolled to date, with 10
evaluable. B doses range from 1.0-1.3mg/m2 per current dose
escalation. Age range was 48-74 years. No patient had resistant
disease at the time of transplant, and only one patient had previ-
ously undergone HDT. Time to WBC and Plt engraftment were
not different from historical cohorts receiving MEL 200 alone. Six
patients have been randomized to the B’before’ arm, and 5 in the
B ‘after’ arm. There was no signiﬁcant difference in myeloma cell
annexin V staining on day -4 between the 2 groups, however there
was an increase in the percent of Annexin V () MM cells for the
group randomized to the ‘after’ arm compared to the ‘before’ arm
(33.3% [after] vs 4.1% [before]). To date there is no difference in
bone marrow IL6 levels between the 2 randomized groups. Accrual
continues.
Annexin V staining of Myeloma cells in the Marrow
Day -4 Day 0
‘Before’ Arm 0.89 4.08
‘After’ Arm 1.12 33.3
‘Before’ B before M. ‘After’ B after M
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